2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4592 Clonal evolution and survival outcomes in patients with lower-risk myelodysplastic syndromes treated with eltrombopag

Utsav Joshi, MD, Rojesh Shakya2, Bahga Katamesh, MD3, Zachary Thompson, PhD4, Najla Al Ali, MS5, Zhuoer Xie, MD,MS6, Samuel Benjamin Reynolds, MD7, Seongseok Yun, MD, PhD8, Onyee Chan, MD9, Andrew T Kuykendall, MD10, Alison Walker, MD11, David Sallman, MD12, Eric Padron, MD13, Rami Komrokji, MD14, Jeffrey Lancet, MD15, Rory Shallis, MD16
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Moffitt Cancer Center, Tampa, Florida, United States

Introduction: Clinically relevant thrombocytopenia is uncommon in lower-risk (LR) MDS but carries prognostic weight for survival and AML progression. Eltrombopag (EPAG) improves platelet count and bleeding in LR-MDS with acceptable longer-term toxicity (Oliva et al. JCO 2023), but its association with clonal evolution (CE), progression to higher-risk (HR) MDS/AML, and survival remains poorly defined.

Methods: We retrospectively identified patients (pts) aged ≥18 years with MDS and IPSS-R ≤3.5 at EPAG initiation who received EPAG for thrombocytopenia at physician discretion. Baseline characteristics, cytogenetics, next-generation sequencing (NGS) at MDS diagnosis and throughout EPAG treatment were collected. Pts (N=63) were matched to non-EPAG controls (N=459) by 3:1 nearest-neighbor propensity score matching (PSM) without replacement based on age at diagnosis and IPSS-R category. All 63 cases were matched to 189 controls with all standardized mean differences below 0.1. Because cases began follow-up at EPAG initiation, each control received a pseudo-index date equal to its own MDS diagnosis date plus the diagnosis-to-EPAG interval of the matched case, so both groups entered follow-up at the same relative time from diagnosis. Controls with invalid pseudo-index dates (N=73) and cases with no eligible matched control (N=17) were excluded from PSM analysis.

Endpoints were progression-free survival (PFS, defined as a ≥50% relative increase in blasts not yet meeting AML criteria), leukemia-free survival (LFS), and time to CE. CE was measured from baseline NGS at EPAG initiation to first documented CE on serial NGS or cytogenetics or a rise in VAF (>50% relative increase) of a pre-existing variant, censored at last NGS. Kaplan-Meier estimates, matched-set-stratified log-rank tests, and subclass-weighted Cox models were used.

Results: The median age at diagnosis for EPAG pts (N=63) was 73 years (range: 18–88). Most pts (85.7%) presented with good or very good risk cytogenetics. Median IPSS-R at initiation was 3 (range 1.5-3.5); risk was low in 37 (58.7%), intermediate in 15 (23.8%), and very low in 11 (17.5%). EPAG was utilized as first-line therapy in 28 (44.4%) and second-line in 25 (39.7%). Median platelet count at EPAG initiation was 24.5k/uL (range 4-69k) and median EPAG duration was 5.4 months (range 1.0-109.4). Among 54 with a documented reason for stopping, 13 (21%) were refractory, 9 (14.5%) progressed to HR-MDS or AML, and 8 (14.5%) lost response.

Of 63 EPAG-treated pts, 33 (52.4%) had serial NGS evaluable for CE. CE was documented in 22/33 (66.7%; 95% CI 48.2-82), with a median time to CE of 16.6 months (95% CI 9.9-25.5). The most frequent CE events were monosomy 7/del(7q) (n=4), TET2 (n=4), ASXL1, RUNX1, PHF6, STAG2, and SRSF2 (n=3 each), and del(20q), NRAS and TP53 (n=2 each); rest (CUX1, SF3B1, SETBP1, KRAS, FLT3, ETNK1, CBL, DNMT3A, GATA2, NF1, SH2B3, BCOR) were each altered in a single case. The cumulative probability of CE was 16.4% (95% CI 7.2-35.1) at 6 months, 39% (23.7-59.5) at 12 months, 60.6% (42.3-79.3) at 24 months, and 86.9% (68.1-97.3) at 36 months. Serial NGS was unavailable for controls, so CE was assessed descriptively in EPAG pts only.

Peripheral blood and marrow findings were similar at diagnosis between EPAG vs non-EPAG pts except platelet count (median 41.5k vs 146k/uL, p<0.001). del(7q)/-7 (8.7% vs 3.4%, p=0.225) and del(20q) (15.2% vs 7.8%, p=0.157) were comparably distributed; no EPAG case carried del(5q) versus 9.5% of controls (p=0.035). Baseline mutations by NGS did not differ except SF3B1 (EPAG vs non-EPAG, 2.8% vs 23.3%, p=0.012).

PFS did not differ significantly (18/45 vs 19/106 events; median 51 months [95% CI 19.5-not estimable] vs not reached [37.5-not estimable]; 36-month PFS 55% vs 69%) for EPAG and non-EPAG pts, respectively, although the estimated hazard was higher among EPAG pts (HR 1.68, 95% CI 0.92-3.07; p=0.094; stratified log-rank p=0.214). LFS was also not significantly different (6/45 vs 10/109 events; 36-month LFS 84% vs 75% for EPAG and non-EPAG pts, respectively; HR 0.84, 95% CI 0.33-2.13; p=0.71; stratified log-rank p=0.774), with few transformation events.

Conclusion: Although clonal evolution was frequent amongst EPAG pts with LR-MDS these data demonstrate no associated significant excess risk of progression or leukemic transformation. In the absence of a control comparison this observation is descriptive and does not establish a causal relationship.

Utsav Joshi, MD: No relevant conflicts of interest to declare.